Roche vet named Gilead CEO — and Genentech boss moves to Switzerland — in shuffle of top Bay Area biotech execs

The 37th annual J.P. Morgan Healthcare Conference, along with the Biotech Showcase, Startup Health Festival and other conferences in San Francisco this week, feature big names, such as Amgen Inc., Gilead Sciences Inc., Bristol-Myers Squibb Co., Roche .....»»

The company, with sites in the Bay Area, Philadelphia and London, also counts Genentech and a handful of other local biotechs as its competition......»»

Dr. Diana Brainard, a 10-year veteran of Gilead Sciences Inc. who currently heads up the company's broad virology drug pipeline, will take over as CEO of a young cell therapy company backed by her soon-to-be former employer. Starting May 17, Brain.....»»

Gilead Sciences Inc. employees were targeted over the past month by hackers, according to a report by Reuters. The news agency said the attacks, which representatives of three cybersecurity firms indicated had originated from Iran, preceded this wee.....»»

While large swaths of the Charlotte-area workforce are figuring out ways to get their jobs done remotely or with new operational protocols — and still others are laid off or furloughed — amid efforts to slow the spread of the novel coronavirus, s.....»»

Gilead Sciences Inc. said Monday it named Merdad Parsey its chief medical officer, effective Nov. 1. Parsey was most recently a senior vice p.....»»

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Cell therapy pioneer and founder Arie Belldegrun has hatched a plan to find more space in the Bay Area for his portfolio of biotech companies......»»

A South San Francisco startup led by veterans of biotech stalwart Genentech Inc. and its parent company Roche wants to raise $86.25 million in an initial public offering. RAPT Therapeutics Inc. — known until May as FLX Bio Inc. — expects to us.....»»

BrewDog USA’s boss is moving into a global role as a new CEO takes the reins in the U.S. Tanisha Robinson has been named chief disruption officer for the Scotland-based brewery, a role in which she will work the company’s assorted startup ve.....»»

Biotech Analysis Central Pharma News: Roche Abandons Drug, Gilead"s Early Stage Bet, Vaxart"s Phase 2 Failure.....»»

Roche , the world's biggest producer of cancer drugs, is stepping up cost cuts in an efficiency drive made unavoidable by competition from cut-price copies of three mega-brands from its famed U.S. Genentech biotech stable......»»

A South San Francisco company in a race to come up with a treatment for a deadly liver disease wants to raise $75 million in an initial public offering. NGM Biopharmaceuticals Inc. — backed by the venture capital firm managed by Dave Goeddel, the fi.....»»

Gilead Sciences is planning to hire industry veteran Daniel O’Day to take the helm and help the drug company revive sales and recover from a disappointing deal......»»

Drugmaker Gilead Sciences Inc named Roche Holding AG executive Daniel O'Day as its new chief executive officer, the companies said on Monday......»»

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG executive Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum......»»

Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum......»»

Research-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) announced Monday it has named Daniel O'Day as its chairman of the board and CEO, ef Latest Ratings for GILD DateFirm.....»»

Inc. Magazine revealed its sixth-annual Female Founders 250 list, denoting 250 women making moves in the entrepreneurial world. And on this year's list were several familiar faces to the Minnesota startup scene......»»

Many conservatives in southeast Wisconsin business donated to Nikki Haley and Ron DeSantis. What now?.....»»